Inhibrx (INBX) Short Interest Ratio & Short Volume → The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad) Free INBX Stock Alerts $34.75 +0.31 (+0.90%) (As of 03:47 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Inhibrx Short Interest DataCurrent Short Volume2,200,000 sharesPrevious Short Volume2,150,000 sharesChange Vs. Previous Month+2.33%Dollar Volume Sold Short$76.43 millionShort Interest Ratio / Days to Cover3.2Last Record DateApril 15, 2024Outstanding Shares52,280,000 sharesFloat Size35,600,000 sharesShort Percent of Float6.18%Today's Trading Volume367,611 sharesAverage Trading Volume632,344 sharesToday's Volume Vs. Average58% Short Selling Inhibrx ? Sign up to receive the latest short interest report for Inhibrx and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatINBX Short Interest Over TimeINBX Days to Cover Over TimeINBX Percentage of Float Shorted Over Time Ad Priority GoldThe 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. Inhibrx Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20242,200,000 shares $76.43 million +2.3%6.2%3.2 $34.74 3/31/20242,150,000 shares $75.16 million +34.4%6.0%3 $34.96 3/15/20241,600,000 shares $56 million -18.0%4.5%2.1 $35.00 2/29/20241,950,000 shares $71.43 million -7.1%5.5%2.6 $36.63 2/15/20242,100,000 shares $79.78 million -12.5%5.9%3 $37.99 1/31/20242,400,000 shares $92.47 million -41.3%6.7%3.4 $38.53 Get the Latest News and Ratings for INBX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Inhibrx and its competitors with MarketBeat's FREE daily newsletter. 1/15/20244,090,000 shares $142.74 million +20.3%11.5%6.1 $34.90 12/31/20233,400,000 shares $129.20 million -6.1%9.6%7.4 $38.00 12/15/20233,620,000 shares $101.83 million -30.1%10.2%8.9 $28.13 11/30/20235,180,000 shares $107.59 million -2.1%15.0%12 $20.77 11/15/20235,290,000 shares $107.23 million +5.4%15.3%12 $20.27 10/31/20235,020,000 shares $77.66 million +1.0%15.0%11.2 $15.47 10/15/20234,970,000 shares $87.97 million -7.1%14.9%10.5 $17.70 9/30/20235,350,000 shares $98.17 million +11.2%16.0%11.9 $18.35 9/15/20234,810,000 shares $100.58 million -5.5%14.4%11.3 $20.91 8/31/20235,090,000 shares $108.93 million -12.8%15.3%12.8 $21.40 8/15/20235,840,000 shares $99.69 million +1.7%17.5%15.7 $17.07 7/31/20235,740,000 shares $115.09 million +0.9%18.0%16.4 $20.05 7/15/20235,690,000 shares $138.32 million -1.4%17.9%17 $24.31 6/30/20235,770,000 shares $149.79 million -4.0%18.2%16 $25.96 6/15/20236,010,000 shares $167.20 million +1.0%20.4%15.8 $27.82 5/31/20235,950,000 shares $140.78 million +3.3%20.2%15.4 $23.66 5/15/20235,760,000 shares $144.86 million +0.4%19.6%13.8 $25.15 4/30/20235,740,000 shares $120.54 million -2.1%19.5%14.1 $21.00 4/15/20235,860,000 shares $106.95 million -0.3%19.9%15.1 $18.25 3/31/20235,880,000 shares $110.96 million -3.0%20.0%14.5 $18.87 3/15/20236,060,000 shares $136.71 million +7.8%20.6%14.4 $22.56 2/28/20235,620,000 shares $135.22 million +8.5%19.1%12.9 $24.06 2/15/20235,180,000 shares $120.90 million -1.7%17.6%12.3 $23.34 1/31/20235,270,000 shares $131.75 million -3.0%19.1%11.7 $25.00 1/15/20235,430,000 shares $128.47 million +26.3%18.1%11.3 $23.66 12/30/20224,300,000 shares $105.95 million +8.6%14.4%8.5 $24.64 12/15/20223,960,000 shares $110.96 million -10.8%13.2%5.4 $28.02 11/30/20224,440,000 shares $133.11 million -1.1%15.7%5.7 $29.98 11/15/20224,490,000 shares $146.82 million -2.8%15.9%5.8 $32.70 10/31/20224,620,000 shares $148.67 million +16.7%18.0%6.2 $32.18 10/15/20223,960,000 shares $118.21 million -4.1%15.5%5.5 $29.85 9/30/20224,130,000 shares $74.13 million +25.5%16.2%5.9 $17.95 9/15/20223,290,000 shares $48.66 million +0.6%12.9%6.9 $14.79 8/31/20223,270,000 shares $58.01 million +0.3%12.8%7.2 $17.74This 1 Biotech Stock has been shocking the markets (Ad)Save the Date: BioStem's 2024 Q1 Call Coming Up!Sign Up for the Live Broadcast here INBX Short Interest - Frequently Asked Questions What is Inhibrx's current short interest? Short interest is the volume of Inhibrx shares that have been sold short but have not yet been closed out or covered. As of April 15th, traders have sold 2,200,000 shares of INBX short. 6.18% of Inhibrx's shares are currently sold short. Learn More on Inhibrx's current short interest. What is a good short interest ratio for Inhibrx? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. INBX shares currently have a short interest ratio of 3.0. Learn More on Inhibrx's short interest ratio. Which institutional investors are shorting Inhibrx? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Inhibrx: Equitec Proprietary Markets LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Inhibrx? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 6.18% of Inhibrx's floating shares are currently sold short. Is Inhibrx's short interest increasing or decreasing? Inhibrx saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 2,200,000 shares, an increase of 2.3% from the previous total of 2,150,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Inhibrx's float size? Inhibrx currently has issued a total of 52,280,000 shares. Some of Inhibrx's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Inhibrx currently has a public float of 35,600,000 shares. How does Inhibrx's short interest compare to its competitors? 6.18% of Inhibrx's shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Inhibrx: Fusion Pharmaceuticals Inc. (5.73%), Beam Therapeutics Inc. (16.00%), ADMA Biologics, Inc. (3.55%), Ginkgo Bioworks Holdings, Inc. (19.74%), Neumora Therapeutics, Inc. (11.07%), Recursion Pharmaceuticals, Inc. (26.39%), Tarsus Pharmaceuticals, Inc. (20.91%), Sana Biotechnology, Inc. (21.81%), 4D Molecular Therapeutics, Inc. (19.21%), Apogee Therapeutics, Inc. (12.97%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Inhibrx stock? Short selling INBX is an investing strategy that aims to generate trading profit from Inhibrx as its price is falling. INBX shares are trading up $0.31 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Inhibrx? A short squeeze for Inhibrx occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of INBX, which in turn drives the price of the stock up even further. How often is Inhibrx's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including INBX, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: FUSN Short Squeeze BEAM Short Squeeze ADMA Short Squeeze DNA Short Squeeze NMRA Short Squeeze RXRX Short Squeeze TARS Short Squeeze SANA Short Squeeze FDMT Short Squeeze APGE Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:INBX) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersThis 1 Biotech Stock has been shocking the marketsHuge Alerts1970’s computer coder Issues Shocking AI WarningInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 Media